🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT06859268
Active, not recruiting Phase 3

A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity

NCT06859268 · tracked via the Priya Life Science USA tracker
Sponsor
Eli Lilly and Company
Phase
Phase 3
Started
2025-03-05
Last updated
2026-03-03

Condition(s) studied

Obesity

Investigational drug(s) / intervention(s)

RetatrutidePlacebo

Retatrutide: Administered SC

Placebo: Administered SC

Study summary

This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss. The study will have two treatment phases: an 80 week lead-in phase in which all participants will take retatrutide dose 1 and a 36 week randomized, double-blinded phase in which participants will either take retatrutide dose 1, retatrutide dose 2, or switch to placebo. Participation in the study will last around 125 weeks.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * Have obesity and a history of at least one self-reported unsuccessful dietary effort to reduce body weight Exclusion Criteria: * Have a self-reported change in body weight \>5 kilograms (kg) (11 pounds) within 90 days before screening * Have a prior or planned surgical treatment for obesity * Have a prior or planned endoscopic procedure and/or device-based therapy for obesity * Have Type 1 Diabetes, Type 2 Diabetes, or any other type of diabetes * Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2) * Have had within the past 90 days before screening: * acute myocardial infarction * cerebrovascular accident (stroke) * hospitalization for unstable angina, or * hospitalization due to congestive heart failure * Have New York Heart Association Functional Classification Class IV congestive heart failure * Have a history of chronic or acute pancreatitis * Have taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening

Primary outcome measure(s)

Trial sites (53)

FacilityCityRegionStatus
Southern California Clinical Research Santa Ana California
University of Colorado Anschutz Medical Campus Aurora Colorado
CMR of Greater New Haven, LLC Hamden Connecticut
ALL Medical Research, LLC Cooper City Florida
Florida International Medical Research Coral Gables Florida
Renstar Medical Research Ocala Florida
Charter Research - Winter Park Orlando Florida
Metabolic Research Institute, Inc. West Palm Beach Florida
Kubost Clinical Research - Marietta Marietta Georgia
North Georgia Clinical Research Woodstock Georgia
Pacific Diabetes & Endocrine Center Honolulu Hawaii
Alliance for Multispecialty Research, LLC Oak Brook Illinois
Springfield Clinic Main Campus Springfield Illinois
Alliance for Multispecialty Research, LLC Lexington Kentucky
L-MARC Research Center Louisville Kentucky
Pennington Biomedical Research Center Baton Rouge Louisiana
Care Access - Lake Charles (Bayou Pines) Lake Charles Louisiana
Massachusetts General Hospital Boston Massachusetts
Alliance for Multispecialty Research, LLC Kansas City Missouri
Vector Clinical Trials Las Vegas Nevada
Dent Neurosciences Research Center, Inc Amherst New York
Carteret Medical Group Morehead City North Carolina
Care Access - Raleigh Raleigh North Carolina
Tekton Research, LLC. Moore Oklahoma
Altoona Center For Clinical Research Duncansville Pennsylvania
Care Access - Rapid City Rapid City South Dakota
Alliance for Multispecialty Research, LLC Knoxville Tennessee
Care Access - Houston Houston Texas
Southern Endocrinology Associates Mesquite Texas
Sleep Therapy Research Center San Antonio Texas
National Clinical Research, Inc Richmond Virginia
Northwest Clinical Research Center Bellevue Washington
Central Washington Health Services Association d/b/a Confluence Health Wenatchee Washington
Aggarwal and Associates Limited Brampton Canada
Circulate Cardiac & Vascular Centre Burlington Canada
Med Trust Research Courtice Canada
Winterberry Research Inc. Hamilton Canada
Centre de Medecine Metabolique de Lanaudiere (CMML) Terrebonne Canada
Care Access - Thunder Bay - Barton Street Thunder Bay Canada
Maple Leaf Research Toronto Canada

+ 13 more sites — see the full list on the official registry below.

More Eli Lilly and Company trials in the USA

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06859268 on ClinicalTrials.gov ↗ ← All trials in the USA